RIGL

Rigel Pharmaceuticals' stock (RIGL) has shown significant movement, trading between $24.95 and $52.24 over the past 52 weeks, and as of September 28, 2026, it was $49.39, marking a 71.79% increase year-over-year. Key events include the May 2026 announcement of in-licensing Veppanu, a new breast cancer treatment, which was seen as a pivot in growth strategy. In May 2026, Q1 financial results reported GAAP earnings of $0.44 per share, missing estimates, despite revenues rising over 10% year-over-year. Alison Hannah was appointed EVP and Chief Medical Officer in July 2026. In August 2026, Q2 financial results significantly beat analyst expectations with $0.88 EPS and $78.7 million in revenue, leading to a 16.5% stock increase over 60 days, and Veppanu commercially launched. Rigel participated in investor conferences in September 2026 and announced inducement grants in October 2026. By October 10, 2026, the stock broke above its 200-day moving average, with analysts generally holding a 'Moderate Buy' rating and an average price target of $59.00, with some firms raising their targets significantly.